Bronchiolitis is a viral-induced lower respiratory tract infection (LRTI) that occurs predominantly in children <2 years of age, particularly infants.
The most frequent cause of severe bronchiolitis is respiratory syncytial virus (RSV) infection, with other respiratory viruses (para-influenza virus (PIV), influenza virus, human metapneumovirus (hMPV) and measles virus) being less common or for which definitive attribution is yet to be established (e.g. rhinovirus (RV), bocavirus and coronavirus) ( Table 1) .
Epidemiology
Epidemiological studies on bronchiolitis often include all children presenting with physician-diagnosed LRTI, and may overestimate the true incidence of bronchiolitis alone.
In a prospective, hospital-based surveillance study of 8 723 child ren under-5 with physician-diagnosed LRTI, from five sites in four provinces in South Africa (SA), from 2009 to 2012 (severe acute respiratory illness (SARI) programme), the overall prevalence of respiratory viruses was 78%. The viruses that were isolated included RV in 37%, RSV in 26%, adenovirus in 26%, influenza virus in 7% and hMPV in 5%. [2] In 2009 and 2010, this surveillance study evalua ted respiratory viruses by a 10-plex real-time reverse-transcription polymerase chain reaction (rRT-PCR). [3] Respiratory viral co-infections among cases enrolled indicated 39.6% with single viral infections, while 17.4% had ≥2 viral co-infections. [3] 
RV
Many studies show RV to be associated with bronchiolitis; however, the high prevalence of RV in healthy asymptomatic children limits definitive attribution of its role in the pathogenesis of bronchio litis. Early studies have suggested that oxygen saturation is generally not as low in children with RVassociated bronchiolitis as in those with RSV-associated bronchio litis. [4] However, more recent studies suggest that RV may be more sinister. [5] All three types of RV have been identified in SA, although RV-A and RV-C are more common than RV-B. RV is associated with symptomatic respiratory illness; however, there is no association between RV type and disease severity. [6] RV-D has subsequently been identified. [7] Bronchiolitis is a viral-induced lower respiratory tract infection that occurs predominantly in children <2 years of age, particularly infants. Many viruses have been proven or attributed to cause bronchiolitis, including and most commonly the respiratory syncytial virus (RSV) and rhinovirus. RSV is responsible for more severe disease and complications (including hospitalisation) in bronchiolitis patients. Whereas bronchiolitis is exclusively due to respiratory viral infections, with little evidence of bacterial co-infection, the former could nevertheless predispose to superimposed bacterial infections. Although data support an interaction between RSV and pneumococcal superimposed infections, it should be noted that this specifically refers to children who are hospitalised with RSV-associated pneumonia, and not to children with bronchiolitis or milder outpatient RSV-associated illness. As such, empiric antibiotic treatment against pneumococcus in children with RSV-associated pneumonia is only warranted in cases of hospitalisation and when the clinical syndrome is more in keeping with pneumonia than uncomplicated bronchiolitis. In South Africa, the peak in the RSV season varies only slightly by province, with onset in February, and lasting until June. The important implication of these new seasonality findings is that where prophylaxis is possible, as in the case of RSV, it should be commenced in January of each year.
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RSV
The two major RSV subgroups are A (RSV-A) and B (RSV-B), which are further characterised into several genotypes, based on antigenic and genetic variability of the second hypervariable region of the G-protein. Several genotypes can co-circulate in a single epidemic season, and different genotypes can dominate in consecutive seasons. Over a 15-year study period in SA, RSV-A and RSV-B genotypes evolved, resulting in replacement of all genotypes over the study period. [8] Whereas genotype A virus, rather than RSV-B, has more frequently been associated with more severe disease, other studies have occasionally reported more severe disease with RSV-B than RSV-A. These differences could be related to the extent of community immunity to the specific genotype, with more severe disease observed in the presence of lower community immunity to that strain.
RSV is the most common cause of moderate or severe bronchiolitis and a leading cause of LRTI among young children. RSV-associated bronchiolitis occurs most frequently in infancy, being 2 -3 times higher than in children >5 years. Infection with RSV does not result in permanent or long-term immunity, as re-infections, albeit of lesser severity, are common and may be experienced throughout life. [9] An estimated 33.8 million new episodes of RSV-associated acute lower respiratory tract infection (ALRTI) occurred worldwide in 2005 in children under-5 (22% of episodes), with at least 3.4 (2.8 -4.3) million episodes necessitating hospital admission. An estimated 66 000 -199 000 children under-5 died from RSV-associated ALRTI in 2005, with 99% of these deaths occurring in developing countries. [10] In the SARI surveillance programme, the prevalence of RSV among 4 293 LRTI hospitalisations in under-5 children was 27%, including 863 of 1 157 (75%) <12 months of age, of whom 637 (74%) were <6 months old. Nine of 1 153 children with RSV-associated ALRTI died (case fatality proportion 1%), which was lower than the 2% (74 of 3 122) of children in whom RSV was not identified (p<0.001). Children admitted with RSV-associated ALRTI were younger than those who tested RSV negative (adjusted odds ratio (AOR) 2.8; 95% confidence interval (CI) 2.1 -3.7 for age <6 months v. 23 -59 months). Also, patients with RSV-associated ALRTI were more likely to present with cough (AOR 9.0; 95% CI 5.5 -14.9) and lower-chest retractions (AOR 1.4; 95% CI 1.2 -1.7) than children with non-RSV-associated ALRTI. [11] The incidence of RSV-associated severe ALRTI in children from developing and developed countries (5.5/1 000 v. 5.6/1 000) is equal, but the case fatality rate is higher in the former (2.1% v. 0.3 -0.7%).
[10] The case fatality rate for individual risk factors for RSV-associated disease among children with chronic lung disease is 3.5 -23.0%, congenital heart defects (CHDs) 2 -37%, nosocomial infection 0 -12.2%, intensive care unit admission 1.1 -8.8%, and prematurity 0.6 -1.0%. [12] The risk of mortality with RSV disease increases threefold among haemodynamically significant (complex disease with pulmonary hypertension) CHDs. [13] HIV is associated with a 2 -3-fold greater risk of RSV disease and also with higher case fatality proportions (12% v. 2% in HIV-uninfected children). [11] 
Bacterial-viral interactions
Whereas bronchiolitis is exclusively due to respiratory viral infections, with little evidence of bacterial co-infection, [14] the former could nevertheless predispose to superimposed bacterial infections. [15] These complicated cases of respiratory viral infections present with the more classic signs of pneumonia, including alveolar consolidation on chest radiographs, raised C-reactive protein (≥40 mg/dL), temperature ≥38°C, crepitations and bronchial breathing on chest auscultation. The role of bacterial coinfections in children with a respiratory virus-associated pneumonia is frequently underemphasised owing to limited tools for diagnosing bacterial pneumonia, with blood culture sensitivity ranging from 3% to 18% for detecting pneumococcal pneumonia. [16] However, epidemiological studies have identified a strong temporal association between some respiratory viruses and invasive pneumococcal disease. Included among these are studies on the temporal association of the influenza virus and RSV epidemics and invasive pneumococcal disease. [17] Further evidence for this association was observed in an SA randomised controlled trial of an investigational 9-valent pneumococcal conjugate vaccine (PCV), in which children vaccinated with PCV had a 32% lower risk of being hospitalised for a viral-associated pneumonia compared with placebo recipients. [18] This lower risk of respiratory virus-associated hospitalisation was evident for influenza virus, hMPV and RSV-associated pneumonia. [19] The biological rationale for the reduction in respiratory virus-associated pneumonia among the PCV-vaccinated children in this study, was attributed to vaccination having prevented the superimposed vaccine-serotype pneumococcal co-infection, which would have led to progression to more severe disease -culminating in hospitalisation among the placebo recipients. Notably, there was no reduction in hospitalisation for bronchiolitis among the PCV9 vaccinated children, corroborating that pneumococcal co-infection was unlikely to have played a role in the pathogenesis of bronchiolitis.
The pathogenesis of increased susceptibility to pneumococcal infection following RSV infection in mice-model studies has been attributed to RSV G glycoprotein-binding penicillin-binding protein 1a increasing pneumococcal virulence owing to up-regulation of virulence genes, pneumococcal toxin and pneumolysin. This could lead to an increase in the inflammatory response and bacterial adherence to human ciliated epithelial cultures. [20, 21] This again is corroborated by studies in children with alveolar pneumonia associated with RSV or RV infection, among whom higher pneumococcal bacterial load was observed in the nasopharynx than in children with RSV or RV in the absence of alveolar consolidation. [22] Observations from the SA study were recently corroborated by an ecological study in the USA, in which RSV and pneumococcal pneumonia were shown to share a distinctive spatiotemporal pattern, with RSV associated with a significant increase in the incidence of pneumococcal pneumonia in children <1 year of age (attributable percent (AP) 20.3%; 95% CI 17.4 -25.1%) and among children aged 1 -2 years (AP 10.1%; 95% CI 7.6 -13.9%). Similarly, influenza was associated with an increase in pneumococcal pneumonia among children aged 1 -2 years (AP 3.2%; 95% CI 1.7 -4.7%). After the introduction of PCV7 into the USA immunisation programme examining physician-coded diagnosis, the authors observed a decline in RSV-coded hospitalisations for children <1 year old (AP −18.0%; 95% CI −22.6 to −13.1% for 2004/2005 -2008/2009 v. 1997/1998 -1999/2000) . [23] Although the abovementioned data support an interaction between RSV and pneumococcal superimposed infections, these specifically refer to children who are hospitalised with RSV-associated pneumonia and not to those with bronchiolitis or milder outpatient RSV-associated illness. As such, empiric antibiotic treatment against pneumococcus with RSV-associated pneumonia is only warranted in a child who is hospitalised and whose clinical syndrome is more in keeping with pneumonia than uncomplicated bronchiolitis.
Seasonality
There are several factors responsible for an outbreak of RSV infection. These include geographical locations (latitude and altitude) and climatic factors (temperature, barometric pressure, relative humidity, CME vapour tension, hours of light, precipitation, dewpoint). In most temperate regions, such as the USA and Europe, RSV outbreaks last an average of 3 -4 months, with a peak incidence during winter, although the exact timing of onset of the outbreak is uncertain. In tropical regions, RSV outbreaks are not distinctly related to season, but often occur during the hottest rainy season. In SA, the peak in RSV season varies slightly by province, with onset of the epidemic usually in KwaZulu-Natal in December -January, in Gauteng in February -March, and followed by the Western Cape in March. [24] In 2009 and 2010, the SARI programme reported seasonality for RSV, influenza A and B viruses, enterovirus, hMPV, and PIV type 3. RSV circulation was evident from February to June, before the influenza season, which occurred from May to September. Peak activity for hMPV was observed between July and August and for PIV type 3 between September and November. Adenovirus and RV were identified perennially without any obvious peaks, while PIV types 1 and 2 were detected sporadically throughout the 2 years. [3] The important implication of these new seasonality findings is that where prophylaxis is possible, as in the case of RSV, it should be commenced in January of each year.
RSV in HIV-infected children
RSV may be identified throughout the year in HIV-infected child ren because of prolonged shedding of the virus (up to 100 days post infection) compared with 5 -7 days in HIV-uninfected children. [25] Although HIVinfected children with RSV-associated ALRTI are at increased risk of hospitalisation and death, this could be due to greater susceptibility to Pneumocystis jirovecii pneumonia and other co-infections. The increased risk of RSV-associated ALRTI hospitalisation in HIV-infected children is greatest during infancy, but remains high even in the second, third, and fourth years of life. [11] 
Pathophysiology of RSV disease
The viral infection starts in the upper respiratory tract and spreads to the lower tract within a few days, resulting in inflammation of the bronchiolar epithelium and oedema of the submucosa and adventitia. [26] Plugs of sloughed, necrotic epithelium and fibrin and excessive mucus secretion add to airway obstruction, causing partial or total obstruction to airflow. [27] A 'ball-valve' mechanism can result in trapping of air distal to obstructed areas, with subsequent absorption, atelectasis, and a mismatch of pulmonary ventilation and perfusion that may lead to hypoxaemia. Smooth-muscle constriction seems to have a minor role in the pathological process, which may explain the limited benefit of bronchodilators observed in clinical studies. [26] Although these mechanisms are known for RSV bronchiolitis, it is assumed that other viruses produce similar pathological conditions.
